IL1B and Alzheimer disease: The reduced BBB penetration of Anakinra, an IL-1 receptor antagonist, and canakinumab, a IL-1β neutralizing antibody, have limited their application in AD [256], and might also be why most of the clinical data on the use on nonsteroidal anti-inflammatory drugs (NSAIDs) in AD yielded negative results [257].